CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 121 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Escitalopram 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01728194
NCT01728194Phase 4Completed
CompareCT.gov

White Matter and Emotional and Cognitive Control in Late-Onset Depression

Weill Medical College of Cornell University·interventional·Posted Nov 16, 2012·Updated Oct 6, 2020

In Brief

A Phase 4 clinical trial evaluating Escitalopram and Magnetic Resonance Imaging for Depression. Completed, enrolled 121 participants across 2 sites.

Detailed Summary

This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 16, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 13.6 years ago

Interventions

Escitalopramdrug

20 mg target dose for 12 weeks

Magnetic Resonance Imagingother

Structural and functional MRI of the brain for research purposes.